467 institutions hold shares in Novavax Inc. (NVAX), with 274.75k shares held by insiders accounting for 0.37% while institutional investors hold 53.90% of the company’s shares. The shares outstanding are 65.79M, and float is at 62.53M with Short Float at 7.91%. Institutions hold 53.70% of the Float.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
The top institutional shareholder in the company is Vanguard Group, Inc. (The) with over 5.6 million shares valued at $624.32 million. The investor’s holdings represent 7.58% of the NVAX Shares outstanding. As of Dec 30, 2020, the second largest holder is Blackrock Inc. with 5.13 million shares valued at $571.57 million to account for 6.94% of the shares outstanding. The other top investors are RA Capital Management, L.P. which holds 3.79 million shares representing 5.13% and valued at over $422.46 million, while FMR, LLC holds 2.37% of the shares totaling 1.75 million with a market value of $195.21 million.
Novavax Inc. (NASDAQ: NVAX) is 54.04% higher on its value in year-to-date trading and has touched a low of $14.38 and a high of $331.68 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The NVAX stock was last observed hovering at around $178.76 in the last trading session, with the day’s loss setting it -6.99% off its average median price target of $317.00 for the next 12 months. It is also 52.94% off the consensus price target high of $365.00 offered by 5 analysts, but current levels are 39.73% higher than the price target low of $285.00 for the same period.
Currently trading at $171.77, the stock is -12.62% and -21.69% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.85 million and changing -3.91% at the moment leaves the stock 23.12% off its SMA200. NVAX registered 966.89% gain for a year compared to 6-month gain of 55.91%. The firm has a 50-day simple moving average (SMA 50) of $210.81 and a 200-day simple moving average (SMA200) of $149.03.
The stock witnessed a 8.80% loss in the last 1 month and extending the period to 3 months gives it a 47.77%, and is -0.89% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.12% over the week and 9.06% over the month.
Novavax Inc. (NVAX) has around 791 employees, a market worth around $12.38B and $475.60M in sales. Fwd P/E is 5.23. Profit margin for the company is -87.90%. Distance from 52-week low is 1094.51% and -48.21% from its 52-week high. The company has generated returns on investments over the last 12 months (-38.00%).
Novavax Inc. (NVAX) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Novavax Inc. (NVAX) is a “Buy”. 5 analysts offering their recommendations for the stock have an average rating of 2.00, where 0 rate it as a Hold and 0 think it is a “Overweight”. 5 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Novavax Inc. is expected to release its quarterly report on 08/10/2021 and quarterly earnings per share for the current quarter are estimated at -$2.65 with sales reaching $291.87M over the same period.The EPS is expected to shrink by -32.00% this year, but quarterly earnings will post 754.80% year-over-year. Quarterly sales are estimated to grow 8,542.90% in year-over-year returns.
Novavax Inc. (NVAX) Insider Activity
A total of 194 insider transactions have happened at Novavax Inc. (NVAX) in the last six months, with sales accounting for 147 and purchases happening 47 times. The most recent transaction is an insider sale by Trizzino John, the company’s EVP, Chief Commercial Officer. SEC filings show that Trizzino John sold 191 shares of the company’s common stock on Apr 07 at a price of $178.03 per share for a total of $34004.0. Following the sale, the insider now owns 287.0 shares.
Novavax Inc. disclosed in a document filed with the SEC on Apr 05 that Trizzino John (EVP, Chief Commercial Officer) sold a total of 3,021 shares of the company’s common stock. The trade occurred on Apr 05 and was made at $190.10 per share for $0.57 million. Following the transaction, the insider now directly holds 287.0 shares of the NVAX stock.
Still, SEC filings show that on Mar 26, Herrmann John A III (EVP, Chief Legal Officer) disposed off 2,894 shares at an average price of $186.80 for $0.54 million. The insider now directly holds 275 shares of Novavax Inc. (NVAX).